Jason D. Fontenot - Feb 25, 2022 Form 4 Insider Report for SANGAMO THERAPEUTICS, INC (SGMO)

Role: SVP, Chief Scientific Officer
Signature: Jason D. Fontenot, by /s/ Ron A. Metzger, Attorney-in-Fact
Stock symbol: SGMO
Transactions as of: Feb 25, 2022
Transactions value $: -$36,863
Form type: 4
Date filed: 3/1/2022, 04:18 PM
Next filing: Apr 27, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SGMO	Common Stock	Tax liability	-$36.9K	-6.25K	-9.59%	$5.90	58.9K	Feb 25, 2022	Direct	F1, F2, F3, F4
transaction	SGMO	Common Stock	Award	$0	+45.1K	+76.58%	$0.00	104K	Feb 25, 2022	Direct	F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SGMO	Stock Option (Right to Buy)	Award	$0	+122K		$0.00	122K	Feb 25, 2022	Common Stock	122K	$5.90	Direct	F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents shares underlying the portions of restricted stock unit ("RSU") grants that vested on February 25, 2022 which were surrendered by the Reporting Person to the Issuer for tax withholding using the Issuer's closing stock price on February 25, 2022 of $5.90/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP").
F2	Includes: (a) 7,565 shares resulting from the February 25, 2022 sole annual vesting installment of the Reporting Person's February 25, 2021 RSU grant, (b) 6,304 shares resulting from the February 25, 2022 vesting of the Reporting Person's February 25, 2020 RSU grant and 8,335 shares subject to such RSU grant that will vest in one final annual installment on February 25, 2023, (c) 5,548 shares resulting from the February 25, 2022 vesting of the Reporting Person's February 25, 2021 RSU grant and 14,667 shares subject to such RSU grant that will vest in two remaining annual installments of 7,333 shares and 7,334 shares on February 25, 2023 and 2024, respectively, and (see footnote 3)
F3	(d) 3,334 shares subject to the Reporting Person's April 25, 2019 RSU grant that will vest in one final annual installment on April 25, 2022. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.
F4	Includes 1,953 shares acquired on April 30, 2021 and 692 shares acquired on October 29, 2021 under the Issuer's 2010 Employee Stock Purchase Plan.
F5	Represents shares of common stock issuable upon settlement of an RSU grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.
F6	One-quarter (1/4) of the shares subject to the option will vest and become exercisable on the first anniversary of the grant date, and the remainder of the shares will vest and become exercisable in 24 successive equal monthly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.